CD38 and AL amyloidosis: Beneficial features of adaptive NK cells are currently under development from third-party donor cells and engineered iPSC NK cells, mainly focused on NKG2C, FcεRIγ, and CD38 negativity in combination with daratumumab for multiple myeloma.48 49 Like the ‘g-NK cells’,48 ADAPT-NK cells circumvent the need for genetic engineering while relying on pre-selection of donors harboring adaptive NK subpopulations.